MedTrace Logo

Relative Bioavailability Study of SHR3680

NCT04903158 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-05-26

No results posted yet for this study

Summary

This is a single-center, single-dose, randomized, open-label, parallel sstudy to evaluate the relative bioavailability of new and old formulations of SHR3680 tablets in healthy male subjects under fasting conditions.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

test SHR3680 tablets

Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)

DRUG

reference SHR3680 tablets

subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2021-03-15
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04903158 on ClinicalTrials.gov